2,3-二甲基-1,2,3,4-四氢异喹啉 | 54365-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 2,3-二甲基-1,2,3,4-四氢异喹啉
• 英文名称: 2,3-Dimethyl-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 2,3-dimethyl-1,2,3,4-tetrahydro-isoquinoline；2,3-Dimethyl-1,2,3,4-tetrahydro-isochinolin；2,3-Dimethyl-1,2,3,4-tetrahydroisochinolin；2,3-dimethyl-3,4-dihydro-1H-isoquinoline
• CAS: 54365-72-9
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: OSHNQAZTSFMABP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  2,3-二甲基-1,2,3,4-四氢异喹啉 、 2-iodo-1-(3-nitrophenyl)ethanone 生成 2,3-dimethyl-2-(3-nitro-phenacyl)-1,2,3,4-tetrahydro-isoquinolinium; iodide
  参考文献：
  名称：

  Derivatives of Tetrahydroquinoline and Tetrahydroisoquinoline¹

  摘要：

  DOI：

  10.1021/ja01136a501
• 作为产物：
  描述：

  2,3-dimethylisoquinolinium iodide 在 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 甲酸 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以94%的产率得到2,3-二甲基-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  Transfer Hydrogenation of Isoquinolinium Salts Catalyzed by a Rhodium Complex

  摘要：

  使用HCOOH-Et3N (5:2)作为氢源，以[Cp*RhCl2]2为催化剂，实现了对异喹啉盐的区域和化学选择性转移氢化。通过该催化体系获得了多种高产率的N-甲基和N-苄基-1,2,3,4-四氢异喹啉生物碱。

  DOI：

  10.1055/s-2006-949606

文献信息

• [EN] ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE<br/>[FR] MODULATEURS DE PROTÉOLYSE À BASE D'ALANINE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS INC

  公开号：WO2017011590A1

  公开（公告）日：2017-01-19

  The description relates to inhibitors of Apoptosis Proteins (TAPs) binding compounds, including Afunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the IAP E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

  描述涉及抑制凋亡蛋白（TAPs）结合化合物，包括包含相同的A功能化合物，这些化合物作为靶向泛素化的调节剂发挥作用，特别是根据本发明的双功能化合物抑制各种多肽和其他蛋白质的化合物。具体而言，描述提供了一端含有结合到IAP E3泛素连接酶的配体，另一端含有结合到靶蛋白的基团的化合物，使得靶蛋白靠近泛素连接酶以促使该蛋白的降解（和抑制）。可以合成化合物，表现出与几乎任何类型的靶向多肽的降解/抑制一致的广泛药理活性。
• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• Indium metal as a reducing agent in organic synthesis
  作者：Michael R. Pitts、Justin R. Harrison、Christopher J. Moody

  DOI：10.1039/b101712h

  日期：——

  aromatic nitro compounds under similar conditions results in selective reduction of the nitro groups; ester, nitrile, amide and halide substituents are unaffected. Likewise indium in aqueous ethanolic ammonium chloride is an effective method for the deprotection of 4-nitrobenzyl ethers and esters. Indium is also an effective reducing agent under non-aqueous conditions and α-oximino carbonyl compounds can

  铟的低第一电离能（5.8 eV）及其对空气和水的稳定性表明，这种金属元素应是有机基材的有用还原剂。使用铟金属还原C描述了肟，硝基化合物和共轭烯烃的亚胺中的N键，苯并稠合的氮杂环中的杂环以及4-硝基苄基保护基的去除。因此，使用乙醇氯化铵水溶液中的铟金属选择性地还原喹啉，异喹啉和喹喔啉中的杂环。在相似条件下处理一系列芳香族硝基化合物会导致硝基的选择性还原；酯，腈，酰胺和卤化物取代基不受影响。同样地，乙醇乙醇铵水溶液中的铟是使4-硝基苄基醚和酯脱保护的有效方法。铟在非水条件下也是有效的还原剂，α-肟基羰基化合物可以选择性地还原为相应的N-在乙酸酐或二碳酸二叔丁酯存在下，用铟粉，乙酸在THF中的叔胺保护。在THF-乙酸中的铟也会还原共轭烯烃。
• [EN] MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE<br/>[FR] MODULATEURS DU RÉCEPTEUR DES ŒSTROGÈNES DE PROTÉOLYSE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS INC

  公开号：WO2018140809A1

  公开（公告）日：2018-08-02

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为雌激素受体（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端为 cereblon、Von Hippel-Lindau 配体结合基团、凋亡抑制蛋白或鼠双分子同源物 2 配体的双功能化合物，该化合物与相应的 E3 泛素连接酶结合，并且另一端含有结合靶蛋白的基团，使得靶蛋白与泛素连接酶靠近，以实现对靶蛋白的降解（和抑制）。本公开展示了与靶蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas, Inc.

  公开号：US20180155322A1

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，这些化合物可用作雌激素受体（目标蛋白）的调节剂。特别是，本公开涉及包含在一段至少有一种Von Hippel-Lindau配体、一种cereblon配体、凋亡抑制蛋白配体、小鼠双分钟同源2配体或其组合的双功能化合物，这些配体与相应的E3泛素连接酶结合，在另一端有一个与目标蛋白结合的部分，使得目标蛋白被置于泛素连接酶附近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白降解/抑制相关的广泛药理活性。可以通过本公开的化合物和组合物治疗或预防由目标蛋白聚集或积累引起的疾病或障碍。